Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | CA9 | Q16790 | 9/20 | 0.77 |
| ▸ | CA12 | O43570 | 8/20 | 0.77 |
| ▸ | CA1 | P00915 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.77 |
| ▸ | CA4 | P22748 | 2/20 | 0.77 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.77 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.77 |
| ▸ | HPGD | P15428 | 2/20 | 0.77 |
| ▸ | CA7 | P43166 | 2/20 | 0.77 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.77 |
| ▸ | CA3 | P07451 | 1/20 | 0.77 |
| ▸ | CA6 | P23280 | 1/20 | 0.77 |
| ▸ | CA5A | P35218 | 1/20 | 0.77 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.77 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 3/20 | 0.61 |
| ▸ | PKM | P14618 | 1/20 | 0.59 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.58 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetaldehyde SCHEMBL28028617 | 0.93 | CYP2A6 (0.87) | CYP2A6CA9CA12CA1ALDH1A1 | |
| SCHEMBL23114201 | 0.88 | CYP2A6 (0.77) | CYP2A6CA9CA12CA1ALDH1A1 | |
| Herniarin SCHEMBL17629468 | 0.87 | CA12 (1.00) | CYP2A6CA9CA12CA1ALDH1A1 | |
| Herniarin SCHEMBL29437733 | 0.87 | CA12 (1.00) | CYP2A6CA9CA12CA1ALDH1A1 | |
| Herniarin SCHEMBL61221 | 0.87 | CA12 (1.00) | CYP2A6CA9CA12CA1ALDH1A1 | |
| SCHEMBL29001886 | 0.86 | CYP2A6 (0.76) | CYP2A6CA9CA12CA1ALDH1A1 | |
| SCHEMBL30450765 | 0.86 | CYP2A6 (0.76) | CYP2A6CA9CA12CA1ALDH1A1 | |
| Herniarin SCHEMBL17113785 | 0.85 | CA12 (0.96) | CYP2A6CA9CA12CA1ALDH1A1 | |
| SCHEMBL29001885 | 0.83 | CYP2A6 (0.71) | CYP2A6CA9CA12CA1ALDH1A1 | |
| SCHEMBL28011620 | 0.82 | CYP2A6 (0.68) | CYP2A6CA9CA12CA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107922968-A | Nucleotide for the polymeric marker of unimolecule electronics SNP measure | 哥伦比亚大学董事会 | 2018-04-17 | — | — | CN | claimed |
| US-9127092-B2 | Method for producing polydienes and polydiene copolymers with reduced cold flow | BRIDGESTONE CORPORATION (JP) | 2015-09-08 | — | — | US | claimed |
| US-20140187725-A1 | METHOD FOR PRODUCING POLYDIENES AND POLYDIENE COPOLYMERS WITH REDUCED COLD FLOW | BRIDGESTONE CORPORATION (JP) | 2014-07-03 | — | — | US | claimed |
| EP-0022188-B1 | CO-INITIATOR COMPOSITIONS FOR PHOTOPOLYMERIZATION CONTAINING 3-ACYL-SUBSTITUTED COUMARINS, PHOTOPOLYMERIZABLE COMPOSITION AND PHOTOGRAPHIC ELEMENT | EASTMAN KODAK COMPANY (a New Jersey corporation) (US) | 1984-10-03 | — | — | EP | claimed |
| US-20260102327-A1 | COSMETIC COMPOSITION FOR SKIN IMPROVEMENT CONTAINING LOW-MOLECULAR-WEIGHT COLLAGEN, COLLAGEN WATER, OR COLLAGEN EXTRACT | SOOY-K CO., LTD. (KR) | 2026-04-16 | — | — | US | disclosed |
| US-12408914-B2 | Systems and methods for customizing mechanical strength in stimuli-responsive bioabsorbable materials | CILAG GMBH INTERNATIONAL (CH) | 2025-09-09 | — | — | US | disclosed |
| EP-4543502-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | Cilag GmbH International (CH) | 2025-04-30 | — | — | EP | disclosed |
| US-20240423617-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| US-20240423620-A1 | COMPRESSIBLE SURGICAL ADJUNCTS, CARTRIDGES, AND CARTRIDGE ASSEMBLIES AND METHODS OF MAKING SURGICAL ADJUNCTS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | US | disclosed |
| WO-2024261659-A1 | SYSTEMS AND METHODS FOR CUSTOMIZING MECHANICAL STRENGTH IN STIMULI-RESPONSIVE BIOABSORBABLE MATERIALS | CILAG GMBH INTERNATIONAL (CH) | 2024-12-26 | — | — | WO | disclosed |
| US-20240200081-A1 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | Aptacure Therapeutics Limited (CN) | 2024-06-20 | — | — | US | disclosed |
| EP-4303307-A1 | METHOD FOR PRODUCING FLAVOURS USING O-METHYLTRANSFERASE FROM PLEUROTUS | Justus-Liebig-Universität Gießen Rechtsabteilung (DE) | 2024-01-10 | — | — | EP | disclosed |
| EP-0695753-A1 | Carbapenem derivatives containing a bicyclic substituent, process for their preparation, and their use | ZENECA LIMITED (GB) | 1996-02-07 | — | — | EP | disclosed |
| EP-0489778-A1 | ANTI-INFLAMMATORY ACTIVE INGREDIENTS FOR COSMETIC PREPARATIONS | Henkel Kommanditgesellschaft auf Aktien (DE) | 1992-06-17 | — | — | EP | disclosed |
| WO-1991003232-A1 | ANTI-INFLAMMATORY ACTIVE INGREDIENTS FOR COSMETIC PREPARATIONS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1991-03-21 | — | — | WO | disclosed |
| WO-1991002515-A1 | ANTI-INFLAMMATORY SUBSTANCES FOR COSMETIC PREPARATION | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1991-03-07 | — | — | WO | disclosed |
| WO-1991002514-A1 | ANTI-INFLAMMATORY ACTIVE SUBSTANCES FOR COSMETIC COMPOSITIONS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1991-03-07 | — | — | WO | disclosed |
| EP-0370282-A2 | Anti-inflammatory compounds for cosmetic preparations | Henkel Kommanditgesellschaft auf Aktien (DE) | 1990-05-30 | — | — | EP | disclosed |
| WO-1990004958-A1 | ANTI-INFLAMMATORY ACTIVE INGREDIENTS FOR COSMETIC PREPARATIONS | HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) | 1990-05-17 | — | — | WO | disclosed |
| US-4441969-A | ARYL HYDROXY CARBOXYLIC ACID | OMI INTERNATIONAL CORPORATION (US) | 1984-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240200081-A1 | NUCLEIC ACID MOLECULE CONJUGATE HAVING PROLONGED IN VIVO HALF-LIFE | SOST, FABP1, VEGFA | CYP2A6 1334/4885CA9 896/4885CA12 828/4885 |
| US-20260102327-A1 | COSMETIC COMPOSITION FOR SKIN IMPROVEMENT CONTAINING LOW-MOLECULAR-WEIGHT COLLAGEN, COLLAGEN WATER, OR COLLAGEN EXTRACT | COL2A1, COL14A1, COL1A1 | CYP2A6 2472/4885CA9 135/4885CA12 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.